Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer

Sponsor
Fudan University
Study ID
NCT06355037
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Triple-negative Breast Cancer

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy.

Key Dates

Start date
May 20, 2024
Status verified
Jul 2024
Primary completion
Dec 31, 2024
Completion
Jan 31, 2025

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: quercetin and dasatinib

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months ]

Central Contacts

Related Studies